Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) RegistryJoanna Góra-Tybor, Krzysztof Jamroziak, Ilona Seferyńska et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 2
A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2025Cited by 1
DAC and CLAM are equally effective as early second induction in newly diagnosed AML patients with persistent leukemia in early bone marrow evaluation – a retrospective analysis of Polish Adult Leukemia GroupKamil Brzozowski, Agnieszka Wierzbowska, Agnieszka Pluta et al.|Acta Haematologica Polonica|2024Cited by 0
A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline ResultsAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2024Cited by 0
Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 studyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2025Cited by 0